Samsung Bioepis to Commercialize BYOOVIZ® (ranibizumab) in Europe from January 2026

Contributed by: Business Wire

Tags

Health

Diabetes

Research

Science

Pharmaceutical

Optical

Biotechnology

Samsung Bioepis Co., Ltd.

More Like This

Samsung Bioepis Reaches Settlement Agreement for PYZCHIVA® (ustekinumab) in Europe

Celltrion Expands Biosimilar Portfolio in the European Union Following European Commission Approval of Two Biosimilars

Polpharma Biologics announces commercial launch of Europe’s first Pre-filled Syringe presentation of a ranibizumab biosimilar

Teva Announces Collaboration to Commercialize Formycon’s Biosimilar Candidate to Eylea® (aflibercept) in major parts of Europe and in Israel

Samsung Bioepis Gains European Commission (EC) Approval for Denosumab Biosimilar (OBODENCE™, XBRYK™)

Celltrion Receives Positive CHMP Opinion for Three Biosimilars in the European Union

Kyung-Ah Kim will serve as the President and Chief Executive Officer (CEO) of Samsung Epis Holdings, in addition to her current role as the President and CEO of Samsung Bioepis.

Newly Established Samsung Epis Holdings to Drive Growth for Samsung Bioepis and a New Subsidiary

Samsung Bioepis' European Whitepaper Proposes Solutions to Bridge Policy Gaps that Hinder Healthy Market Competition and Timely Access to Biosimilar Medicines